Newsletter | October 27, 2026

10.27.26 -- The Risk Of Losing Tacit Knowledge In An ADC Tech Transfer

SPONSOR

Phasing out animal testing in biologics safety is no longer a distant goal; it’s an actionable strategy. This application note explores a roadmap built on the internationally recognized 3Rs principles—Reduction, Replacement, and Refinement—plus a fourth: Responsibility. It prioritizes mature alternatives like NGS and the Blazar® platform, while accelerating innovation for complex assays such as tumorigenicity and oncogenicity. It also highlights evolving regulatory guidance, which increasingly endorses molecular methods over in vivo testing. More.

FOCUS ON OUTSOURCING

The Risk Of Losing Tacit Knowledge In An ADC Tech Transfer

In this segment from the Bioprocess Online Live event “Ensuring Successful Technology Transfer In ADC Development,” panelists Sourav Kundu, Ph.D., and Will Olughu, Ph.D., respond to audience questions and reflect on poll results  that identified tacit knowledge as the most difficult aspect of a process to transfer effectively.

Biologics CDMO Selection: Timeline Risks To Watch

Choosing a biologics CDMO means planning for timeline risks. Early evaluation of materials, batch release, technical flexibility, transparency, and partnership can help prevent delays.

What Makes A Base Editor Potent For Therapeutic SNP Correction?

Therapeutic SNP correction requires tailored enzymes and guide RNAs to boost on-target editing, reduce bystander effects, and enable precise conversion.

Handling Demanding Active Ingredients Safely And Efficiently

See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.

A Platform For Advanced AAV Analytics

Advanced AAV analytics use high‑resolution multiplex platforms to assess genome integrity and capsid traits, improving accuracy, speeding development, and supporting regulatory quality control.

Overcome Common Pre-Filled Syringe Challenges Through Partnership

The pre-filled syringe space is one of the fastest growing sectors, offering greater patient safety and lower manufacturing costs. But pre-filled doesn’t translate to easily filled; there are obstacles.

CHO Cell Line Characterization

Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

Restarting A Manufacturing Campus And Revitalizing A Community

A high‑risk facility acquisition in Huntsville became a blueprint for revitalizing a modern pharmaceutical campus. Discover how coordinated action turned a massive shutdown into a renewed manufacturing hub.

Cracking Complexity: Learnings From 70+ Bispecific Antibody Programs

The goal is practical: help development teams make early decisions that balance speed, quality, and risk and support a smoother path to the clinic.

OUTSOURCING SOLUTIONS

•

Improve Viral Titers In Your AAV Program - Lonza

•

Capabilities Update August 2026: CPHI Special Edition - BE Biosol

•

Drug Product Manufacturing: Scaling Product From Bench To Market - Curia

•

Scalable Solutions For High Potent OSD Manufacturing - Recipharm

•

Monoclonal Antibody Development, The Way It's Meant To Be - KBI Biopharma

Connect With Bioprocess Online: